The efficacy of combined treatment with recombinant human tumor necrosis factor-alpha and 5-fluorouracil is dependent on the development of capillaries in tumor

Eur J Cancer. 1990 Feb;26(2):93-9. doi: 10.1016/0277-5379(90)90289-6.

Abstract

The antitumor effects of recombinant human tumor necrosis factor-alpha (rTNF-alpha) and 5-fluorouracil (5-FU) in combination treatment were examined on Meth A fibrosarcoma implanted intradermally in mice. Growth of the tumor was inhibited when rTNF-alpha was given i.v. on day 7 or 11 after implantation, but the effect was countered when 5-FU was additionally given i.p. once a day on days 1-4 after implantation. Conversely, 5-FU given on days 5-8 after implantation augmented the antitumor effects of rTNF-alpha. Injection of carbon particles showed that fine capillaries did not develop in the tumors of mice treated with 5-FU on days 1-4 after implantation, but that a delicate network of capillaries developed in the tumors of both the mice treated with 5-FU on days 5-8 after implantation and the controls given saline. The results show that the timing of 5-FU treatment is important when attempting to enhance the antitumor effects of rTNF-alpha, and suggest that these effects are directly associated with newly formed fine capillaries in the tumor.

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Female
  • Fibrosarcoma / blood supply*
  • Fibrosarcoma / drug therapy
  • Fluorouracil / administration & dosage
  • Mice
  • Mice, Inbred BALB C
  • Neoplasm Transplantation
  • Recombinant Proteins / administration & dosage
  • Tumor Necrosis Factor-alpha / administration & dosage

Substances

  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • Fluorouracil